(HURN) Huron Consulting - Ratings and Ratios
Consultancy, Digital, Healthcare, Education, Commercial
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 31.1% |
| Value at Risk 5%th | 44.4% |
| Relative Tail Risk | -13.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.96 |
| Alpha | 26.42 |
| CAGR/Max DD | 1.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.381 |
| Beta | 0.710 |
| Beta Downside | 0.562 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.46% |
| Mean DD | 6.23% |
| Median DD | 5.30% |
Description: HURN Huron Consulting November 10, 2025
Huron Consulting Group Inc. (NASDAQ:HURN) is a Chicago-based professional services firm that delivers consulting and managed-services solutions to clients in the United States and abroad. The company is organized into three primary operating segments-Healthcare, Education, and Commercial-each of which leverages a mix of performance-improvement, digital, and organizational-transformation capabilities.
Across all segments, Huron offers a broad portfolio that includes financial and operational performance improvement, enterprise-level technology implementations (EHR, ERP, EPM, CRM), data-management and AI/automation services, revenue-cycle outsourcing, capital-advisory, and strategy-innovation consulting. The firm also markets a proprietary software suite, Huron Research, designed to streamline research-administration compliance for academic and research institutions.
According to the FY 2023 Form 10-K, Huron generated approximately **$1.22 billion** in revenue, representing a **~6 % year-over-year increase** driven primarily by higher demand for digital transformation projects in healthcare and higher education. The company posted an **operating margin of roughly 9 %**, which is modestly above the median for the broader Research & Consulting Services sub-industry (≈7 %). However, FY 2024 guidance is pending, so the forward-looking margin outlook remains uncertain.
Key economic and sector drivers that underpin Huron’s growth prospects include: (1) sustained **U.S. healthcare spending growth of ~4 % CAGR**, fueling demand for revenue-cycle optimization and EHR modernization; (2) **state and federal education funding pressures**, prompting institutions to seek cost-reduction and digital-learning solutions; and (3) a **macro-level acceleration in enterprise AI and automation adoption**, which expands the addressable market for Huron’s technology-managed services.
For analysts looking to deepen their assessment, a quick review of Huron’s **customer concentration profile** (≈15 % of revenue from its top five clients) and **historical win-rate on multi-year digital contracts** can provide early signals about earnings stability and growth sustainability.
To explore how these dynamics translate into valuation metrics, you may find it useful to examine Huron’s profile on ValueRay, where comparable peer benchmarks and forward-looking scenario analyses are readily available.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (108.4m TTM) > 0 and > 6% of Revenue (6% = 97.7m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 4.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.91% (prev 11.59%; Δ -2.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 206.6m > Net Income 108.4m (YES >=105%, WARN >=100%) |
| Net Debt (627.0m) to EBITDA (210.1m) ratio: 2.98 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (17.8m) change vs 12m ago -3.67% (target <= -2.0% for YES) |
| Gross Margin 31.58% (prev 31.51%; Δ 0.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 113.3% (prev 108.1%; Δ 5.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.83 (EBITDA TTM 210.1m / Interest Expense TTM 31.4m) >= 6 (WARN >= 3) |
Altman Z'' 3.35
| (A) 0.09 = (Total Current Assets 475.0m - Total Current Liabilities 330.1m) / Total Assets 1.54b |
| (B) 0.39 = Retained Earnings (Balance) 606.0m / Total Assets 1.54b |
| (C) 0.13 = EBIT TTM 182.9m / Avg Total Assets 1.44b |
| (D) 0.57 = Book Value of Equity 598.7m / Total Liabilities 1.04b |
| Total Rating: 3.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.12
| 1. Piotroski 8.50pt |
| 2. FCF Yield 5.53% |
| 3. FCF Margin 11.77% |
| 4. Debt/Equity 1.30 |
| 5. Debt/Ebitda 2.98 |
| 6. ROIC - WACC (= 5.09)% |
| 7. RoE 21.35% |
| 8. Rev. Trend 96.91% |
| 9. EPS Trend 90.86% |
What is the price of HURN shares?
Over the past week, the price has changed by +3.78%, over one month by +1.95%, over three months by +20.93% and over the past year by +39.16%.
Is HURN a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HURN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 178.3 | 4.4% |
| Analysts Target Price | 178.3 | 4.4% |
| ValueRay Target Price | 220.1 | 28.8% |
HURN Fundamental Data Overview November 29, 2025
P/E Trailing = 27.5729
P/E Forward = 19.3424
P/S = 1.753
P/B = 5.696
P/EG = 1.5199
Beta = 0.181
Revenue TTM = 1.63b USD
EBIT TTM = 182.9m USD
EBITDA TTM = 210.1m USD
Long Term Debt = 589.6m USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 650.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 627.0m USD (from netDebt column, last quarter)
Enterprise Value = 3.47b USD (2.84b + Debt 650.9m - CCE 23.9m)
Interest Coverage Ratio = 5.83 (Ebit TTM 182.9m / Interest Expense TTM 31.4m)
FCF Yield = 5.53% (FCF TTM 191.5m / Enterprise Value 3.47b)
FCF Margin = 11.77% (FCF TTM 191.5m / Revenue TTM 1.63b)
Net Margin = 6.66% (Net Income TTM 108.4m / Revenue TTM 1.63b)
Gross Margin = 31.58% ((Revenue TTM 1.63b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Gross Margin QoQ = 30.55% (prev 33.16%)
Tobins Q-Ratio = 2.24 (Enterprise Value 3.47b / Total Assets 1.54b)
Interest Expense / Debt = 1.69% (Interest Expense 11.0m / Debt 650.9m)
Taxrate = 28.67% (12.2m / 42.6m)
NOPAT = 130.4m (EBIT 182.9m * (1 - 28.67%))
Current Ratio = 1.44 (Total Current Assets 475.0m / Total Current Liabilities 330.1m)
Debt / Equity = 1.30 (Debt 650.9m / totalStockholderEquity, last quarter 499.8m)
Debt / EBITDA = 2.98 (Net Debt 627.0m / EBITDA 210.1m)
Debt / FCF = 3.27 (Net Debt 627.0m / FCF TTM 191.5m)
Total Stockholder Equity = 507.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 108.4m / Total Assets 1.54b)
RoE = 21.35% (Net Income TTM 108.4m / Total Stockholder Equity 507.6m)
RoCE = 16.67% (EBIT 182.9m / Capital Employed (Equity 507.6m + L.T.Debt 589.6m))
RoIC = 12.34% (NOPAT 130.4m / Invested Capital 1.06b)
WACC = 7.25% (E(2.84b)/V(3.49b) * Re(8.63%) + D(650.9m)/V(3.49b) * Rd(1.69%) * (1-Tc(0.29)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.20%
[DCF Debug] Terminal Value 79.56% ; FCFE base≈157.4m ; Y1≈194.2m ; Y5≈331.3m
Fair Price DCF = 292.1 (DCF Value 5.04b / Shares Outstanding 17.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.86 | EPS CAGR: 29.35% | SUE: 1.48 | # QB: 1
Revenue Correlation: 96.91 | Revenue CAGR: 16.57% | SUE: 1.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.74 | Chg30d=-0.066 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=8.66 | Chg30d=+0.077 | Revisions Net=+4 | Growth EPS=+13.9% | Growth Revenue=+9.2%
Additional Sources for HURN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle